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Abstract 
Matched healthy and diseased tissues from breast cancer patients were analysed by quantitative 
proteomics. By comparing proteomic profiles of fibroadenoma (benign tumors, 3 patients), DCIS (non-
invasive cancer, 3 patients) and invasive ductal carcinoma (4 patients) we identified protein alterations 
which correlated with breast cancer progression. Three 8-plex iTRAQ experiments generated an average 
of 826 proteins identifications, of which 402 were common. After excluding those originating from 
blood, 59 proteins were significantly changed in tumor compared to normal tissues with the majority 
associated with invasive carcinomas. Bioinformatics analysis identified relationships between proteins in 
this subset including roles in redox regulation, lipid transport, protein folding and proteasomal 
degradation, with a substantial number increased in expression due to Myc oncogene activation. Three 
target proteins, cofilin-1 and p23 (increased in invasive carcinoma) and membrane copper amine 
oxidase 3 (decreased in invasive carcinoma), were subject to further validation. All three were observed 
in phenotype-specific breast cancer cell lines, normal (non-transformed) breast cell lines and primary 
breast epithelial cells by Western blotting, but only cofilin-1 and p23 were detected by multiple reaction 
monitoring mass spectrometry analysis.  All three proteins were detected by both analytical approaches 
in matched tissue biopsies emulating the response observed with proteomics analysis. Tissue microarray 
analysis (361 patients) indicated cofilin-1 staining positively correlating with tumor grade and p23 
staining with ER positive status, both therefore merit further investigation as potential biomarkers. 
 
  




Breast cancer is the most common cancer in women and the second most common of all types. 
Through the application of surgery, radiotherapy, chemotherapy, the development of targeted immune 
and hormone-based therapies and combined treatment, the 5 year survival rate has increased from 50% 
in the 1970’s to currently 80%. Indeed, almost two thirds of women are living more than 20 years after 
treatment. Despite this, 458,000 women died of breast cancer in 2008 and it is the most frequent cause 
of cancer-related death in women in developing regions and numbers in developed countries equal 
those caused by lung cancer. The incidence of breast cancer is highest in Western Europe (increasing by 
11% in women under 50 between 1993- 95 and 2008- 10) and continues to rise in most developed 
countries1. Furthermore, the number of breast cancer-related deaths in women under 50 has reached 
all time highs in United Kingdom in 2010 (http://www.cancerresearchuk.org/cancer-info). Changes in 
lifestyle are contributing significantly to increased prevalence, such as escalating alcohol consumption, 
oral contraception, reproductive behavior, hormone replacement therapy and postmenopausal obesity, 
all identified as factors associated with causing breast cancer2.  Consequently, and despite the progress 
made to date in treating the disease, the constant changing dynamics of breast cancer incidence 
requires continuous investigation to identify new methods of detection and treatment. 
 Extensive research has revealed breast cancer to be a diverse and complex disease that can be 
classified by histopathological morphology, disease progression, tumor size and stage, lymph node 
status and molecular phenotype. Molecular classification of breast cancer defined 5 main different 
phenotypes3, which have contributed significantly towards targeted therapy. With the continuing 
expansion of the breast cancer genome and transcriptome4, further stratification towards personalised 
treatment can be anticipated. This has been invaluable in defining treatment regimens and predicting 
outcome or responsiveness. 
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Histopathological investigation of breast carcinoma delineates two main groups – ductal 
carcinoma of no specific type (NST) and lobular carcinoma, with a number of less common types5. 
Histological features, supported by mammography, can also determine disease progression, through 
well characterised stages that may include benign atypical ductal hyperplasia (ADH), localised pre-
invasive ductal carcinoma in situ (DCIS) or lobular carcinoma in site (LCIS), to the more advanced stages 
of invasive ductal carcinoma or invasive lobular carcinoma, which spread into the surrounding breast 
tissue. In addition, younger women in particular, may develop fibroadenomas, comprising benign 
fibrous lumps, which do not seem to develop into cancerous growth.  
The transition of breast tissue from a benign state to an invasive state capable of uncontrolled 
proliferation is not well understood. Not all DCIS become cancerous and, for those that do, the 
molecular and/or temporal triggers are not known. Only 25 to 50% of DCIS will progress to invasive 
carcinomas if left untreated6 and currently it is not possible for the pathologist or clinician to predict 
which will advance to a more aggressive stage. Treatment options for DCIS include total mastectomy, 
local excision (LE) plus adjuvant radiotherapy (RT), or LE alone, but these treatments in many cases 
prove superfluous and may cause unnecessary side effects, which compromise the quality of patient’s 
lives. 
Biomarkers that offer the possibility of detecting the early onset of disease progression or can 
differentiate between those tumors that remain dormant and those that that will develop into 
aggressive invasive malignancies would provide opportunities for an earlier as well as a more targeted 
intervention, avoiding unnecessary costly treatments and improving survival. Proteomics has been used 
previously to identify early biomarkers, but none have so far progressed to clinical validation. Building 
on a preliminary study7, we have used an iTRAQ proteomics strategy to compare matched normal and 
tumor tissues from Cypriot patients with fibroadenoma (benign), DCIS (pre-invasive) and invasive ductal 
carcinoma (malignant). In Cyprus, a successful population-wide breast cancer screening programme was 
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initiated in 2003 according to EU guidelines. Within Europe, Cyprus has the lowest mortality rate for all 
cancers, except for breast cancer, which is closer to the average, however it is not known if this is 
related to treatment, genetics or some other factor. Our objective is to identify proteins whose 
expression correlates with cancer progression and validate candidates by Western blotting, multiple 
reaction monitoring mass spectrometry (MRM MS) and tissue microarray as possible markers for early 
detection of breast cancer.  
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Materials and Methods 
Patient characteristics and tissue procurement. The CING study protocol and patient consent 
forms were approved by the Cyprus National Bioethics Committee. Patients underwent surgery for 
removal of breast lesions and subsequent histopathological diagnosis. Following inspection by a 
histopathologist, resected specimens were snap frozen in isopentane cooled by liquid nitrogen and 
stored at -80oC. Tissues from the breast lesion and areas identified as normal, at least 5 cm apart, were 
obtained. Biopsies from patients with fibroadenoma, DCIS or invasive ductal carcinoma were selected 
for proteomic analysis. Frozen sections were cut from matched blocks of normal and disease breast 
tissue using a Bight’s cryostat as described previously7. Three 8-plex iTRAQ experiments (A, B and C) 
were performed, each with matched normal and disease cryosections from 10 patients (Table 1). One 
fibroadenoma biopsy (patient 1), was used in all three experiments for inter-experiment evaluation. 
Tissue microarray (TMA) samples were prepared from archival tissue blocks and clinicopathological data 
were obtained from the Leeds Breast Tissue Bank for patients diagnosed with breast cancer cases at the 
Leeds Teaching Hospitals Trust from 1994 to 1997. Ethical approval was given by Leeds (East) Research 
Ethic Committee, reference 06 ⁄Q1206 ⁄180. Primary breast cells were isolated from biopsy material 
collected from a patient undergoing double mastectomy for BRCA1 risk reduction at Bradford Royal 
Infirmary and determined by pathology to be essentially normal. Ethical approval was given by Leeds 
(East) Research Ethic Committee, reference 07 ⁄H1306⁄98+5. 
Cell lines culture conditions. Cancer cell lines were obtained from American Type Culture 
Collection (Manassas, VA) and maintained in RPMI medium containing 10% v/v foetal calf serum (FCS). 
HB2 normal breast cell line was grown on DMEM + Glutamax-1 (Gibco® Life Technologies, Paisley, UK) 
containing 10% FCS supplemented with hydrocortisone (5 µg/ml) and insulin (10 µg/ml), and MCF-10A 
normal breast cells were cultured in MEGM Bullet Kit (Lonza Walkersville, Inc USA), referred to as 
standard growth medium.  
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Protein extraction from cell lines and primary epithelial cells. Cells were harvested by trypsin 
treatment on reaching 90% confluence. Cells were washed three times with PBS to remove residual FCS, 
each time the supernatant decanted and discarded after centrifugation at 1,000 rpm for 5 minutes, and 
the resulting pellet stored at -20oC until required. Pellets equivalent 5 x 106 cells were thawed, 100l of 
urea extraction buffer (7M urea, 2M thiourea, 4% w/v CHAPS, 50mM DTT in PBS pH7.4 containing 
protease inhibitor cocktail [Roche diagnostics GmbH, Germany]) added, vortexed, sonicated and then 
centrifuged. The protein concentration of each cell line extract was measured using the Bradford assay 
(Bio-Rad Laboratories, Hemel Hempstead, UK)8 and then stored as 10l aliquots at -20oC. 
Protein extraction from tissues by solubilisation and sonication. The following proteomics 
methods were applied to each of the three iTRAQ experiment (workflow schematic in Supplementary 
Figure 1). 
Protein extracts were prepared in parallel from matched normal and diseased tissues for four 
patients using a dual lysis buffer7. In brief, for each sample (10 cryosections), RIPA lysis buffer (50 l, PBS 
pH 7.4, 0.1% w/v SDS, 0.25% w/v sodium deoxycholate containing EDTA-free protease inhibitor cocktail) 
was added, subjected to vortexing for 30 minutes at room temperature and sonicated for 20 seconds on 
ice using a Status US70 sonicating probe (Philips Harris Scientific, UK). The samples were centrifuged at 
13,400 rpm for 20 minutes, 4oC and the liquid phase extracted to new tubes. Urea lysis buffer (50 l, 7M 
urea, 2M thiourea, 4% w/v CHAPS, 50mM DTT in PBS containing EDTA-free protease inhibitor cocktail) 
was added to the pellet two times, each time treated with vortexing, sonication and centrifugation, and 
the resulting supernatant combined with the RIPA buffer protein extract. The protein concentration of 
each total extract for each patient matched normal and tumor biopsy was measured using the Bradford 
assay and stored at -20oC.  
Proteomics sample preparation and mass spectrometry analysis. Each protein extract (50 g of 
protein) was precipitated overnight with 100% acetone at -20oC, centrifuged for 20 minutes at 13,400 
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rpm at 4oC and the pellet resuspended in 1M TEAB (Sigma-Aldrich, Poole, UK), 0.1% w/v SDS. Each 
protein sample was reduced with 50 mM DTT for 15 minutes at 60oC, alkylated with 100 mM IAA at 
ambient temperature for 15 minutes and digested with 2 l of a 1mg/ml solution of modified 
sequencing grade trypsin (Roche Diagnostics GmbH, Germany) at 28oC for 18 hours. After digestion, 
each sample was lyophilised, resuspended in TEAB, 0.1% SDS and an iTRAQ reagent (AB Sciex UK 
Limited, Warrington, UK) added as outlined in Table 1, for 2 hours at room temperature. The labelled 
peptides were then combined together, desalted on an Isolute C18 RP LC column (Kinesis Ltd., St. Neots, 
UK) and the eluate lyophilised. The total iTRAQ-labelled peptide sample was resuspended in OffGel 
peptide sample buffer (containing pH 3-10 ampholytes) and applied to an OffGel 3100 (Agilent 
Technologies, Wokingham, UK) IEF system, using a pH 3-10 high resolution strip, for 50kV hours. 
Twenty-four fractions were collected, desalted on Isolute C18 RP cartridges and then lyophilised.  
LC MALDI. OffGel fractions were analysed on an LC Packings UltiMate 3000 capillary HPLC 
system (Dionex, Camberley, Surrey, UK). Lyophilised fractions were resuspended in 6.5 l of 2% 
acetonitrile, 0.05% TFA (mobile phase A), injected and washed on a C18, 300µm x 5mm, 5µm diameter, 
100Å PepMap pre-column (LC Packings, Sunnyvale, CA) before transfer to a C18, 75µm x 15cm, 3µm 
diameter, 100Å PepMap column (LC Packings) and elution of peptides with a linear gradient to 10% to 
40% mobile phase B (80% acetonitrile, 0.05% TFA) over 105 minutes. A total of 384, 75 nl fractions were 
co-deposited with 1.2 l of a saturated CHCA matrix (Bruker Daltonik GmbH, Bremen, Germany) solution 
onto a MTP AnchorChip 800/384 target plate (Bruker Daltonik) using a Proteineer FC fraction collector 
(Bruker Daltonik) and allowed to air-dry. Peptide Calibration Standard II (Angiotensin I, Angiotensin II, 
Substance P, Bombesin, ACTH clip 1-17, ACTH clip 18-39, Somatostatin 28, Bradykinin fragment 1-7 and 
Renin Substrate Tetradecapeptide porcine; covering the mass range 700 Da – 3200 Da, Bruker Daltonik) 
was applied between each group of 4 fractions. Mass spectrometric analysis was carried out using a 
MALDI-TOF/TOF UltraFlex II instrument (Bruker Daltonik), using a 200 Hz smartbeam laser (>250 
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J/pulse) in reflector mode. A fully automated workflow was performed using WarpLC software (version 
1.2), which encompassed data acquisition (FlexControl v3.0), data-processing (FlexAnalysis v3.0 - TopHat 
baseline subtraction, Savitzky-Golay smoothing and SNAP peak detection algorithms), compilation of a 
non-redundant list of peptides from the 384 HPLC fractions, data-dependent MS/MS of each peptide 
using LIFT mode, compilation of the MS/MS fragment mass lists into a batch (WarpLC v1.3). Where there 
was sufficient sample, replicate LC MALDI analyses were performed for each OffGel fraction.  
Database searching. MS/MS fragment mass lists were searched, via Proteinscape v3.0, (Bruker 
Daltonik), using Mascot software version 2.4 (Matrix Science, UK)9 against Swiss-Prot version 2011_12 
containing 20,323 human protein sequences with search parameters: trypsin digestion, 2 missed 
cleavage, variable modification of methionine oxidation, fixed modifications of cysteine 
(carbamidomethylation) and iTRAQ (lysine and N-termini), and a 95% confidence interval threshold 
(p<0.05, Mascot score ≥ 29). A decoy search (based on automatically generated random sequences of 
the same length) was employed to determine the rate of false-positive identifications. For MALDI 
MS/MS data with a precursor mass tolerance of 100 ppm and fragment-ion mass tolerance of 0.7Da, the 
false discovery rate at the identity threshold was an average of 1.82% (S.D. = 1.58%) for 127 LC MALDI 
runs from all three experiments. iTRAQ labelling efficiency was determined by searching MS/MS data 
using iTRAQ as a variable modification, performing a survey of 400 peptides of labelled and non-labelled 
peptides (p<0.05, Mascot score ≥ 29) in the twenty highest scoring proteins from individual LC MALDI 
experiments and calculated to be 96.2%, 98.1% and 98.3% for experiments A, B and C respectively. 
Data processing. Non-redundant protein profiles for each Experiment were created in 
Proteinscape by combining the corresponding LC MALDI datasets. Qualitative (at least one ranked first 
peptide, Mascot score ≥20) and quantitative filters (at least two iTRAQ tumor:normal ratios) were used 
to define each dataset.  The three datasets were further consolidated to a single list of proteins common 
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to all the experiments, each with 12 iTRAQ ratios representative of the 10 patients (one individual 
analysed three times for inter-experimental evaluation).  
Statistical analysis was undertaken using Strata software (Release 9.2). In order to compare 
patient-to-patient protein profiles, the iTRAQ tumor:normal ratios for each protein, for each patient 
were normalised to an average of 1.0. Therefore, tumor:normal ratios with values > 1 signify higher 
levels in tumor compare to normal tissue and tumor:normal ratios with values < 1 represent higher 
levels in normal compare to tumor tissue. The upper and lower 5th, 10th and 25th percentile protein 
populations of the normalised ratios were calculated for each patient.  Proteins were then organised 
based on the average iTRAQ ratio for the four invasive carcinoma patients, so that those proteins that 
were most significantly changed in each disease state could be identified. The iTRAQ ratios were used as 
variables in Principal Component Analysis (PCA) (R Project for Statistical Computing http://www.r-
project.org/) to correlate protein profiles with stages of the disease.  
Protein-protein interactions and network associations for significantly changed components 
were performed using STRING (version 9.05, http://string-db.org/) and Ingenuity Interactive Pathway 
Analysis software (2013 version) respectively. 
Western blot analysis. Protein extracts were prepared from cell lines or from cryosections 
independent of those used for proteomics analysis. Patient samples, equivalent to 30g of protein, were 
mixed with 10l of SDS reducing buffer (for cell lines, 20g of protein was used with 5l of SDS reducing 
buffer), heated to 60oC for 15 minutes and on cooling applied to SDS polyacrylamide gels, with a 4% 
(v/v) stacking gel and 12% (v/v) separating gel in a SDS-PAGE (Laemmli) buffer system. Gels were run on 
a Mini-PROTEAN® 3 Cell system (Bio-Rad, Hemel Hempstead, UK) for 10 minutes at 80V and then 60 
minutes for 150V. Proteins were transferred to a nitrocellulose membrane by electroblotting for 2 hours 
at 85mA in a Mini Trans-Blot® Cell (Bio-Rad, Hemel Hempstead, UK). The blotted membrane was 
incubated in blocking buffer (5% w/v skimmed milk in Tris-buffered saline, 0.05% v/v Tween), then with 
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the appropriate primary antibody (anti-cofilin-1 rabbit polyclonal antibody, Abcam, Cambridge, UK, 1 in 
2000 dilution, anti-p23 mouse [JJ3] monoclonal antibody, Abcam, 1in 1000 dilution, anti-AOC3 mouse 
[Clone 393112] monoclonal antibody, R&D Systems, Minneapolis, US, 1 in 500 dilution, or anti-beta-
actin, mouse monoclonal antibody, Sigma, Dorset, UK, 1 in 5000 dilution) in blocking buffer was 
incubated overnight at 4oC. After removal of the primary antibody with three TBS-Tween buffer washes, 
the appropriate secondary antibody (anti-rabbit IgG-conjugated with horseradish peroxidise, Dako, 
Glostrup, Denmark, 1 in 3,500 dilution or anti-mouse IgG-conjugated with horseradish peroxidise, 
Abcam, 1 in 3,500 dilution), in blocking buffer, was incubated with the membrane for 45 minutes at 
room temperature. The residual secondary antibody was removed with three TBS-Tween washes and 
proteins detected by addition ECL Plus Western Blotting reagent then exposed to X-ray film (GE 
Healthcare, Amersham, UK). 
Multiple reaction monitoring mass spectrometry (MRM MS). MRM MS was performed on a 
Waters Quattro Ultima triple quadruple mass spectrometer with on-line Waters Alliance 2695 HPLC 
Separation system and 996 Diode array Detector. A two-stage HPLC gradient using solvent A (90% water, 
10% methanol, 0.1% formic acid) and solvent B (80% methanol, 20% water, 0.1% formic acid) on a Luna 
C18 column (2 mm ID x 25 cm length, 5m particle size, Phenomenex Inc., Macclesfield, UK) was used for 
separation of the target peptides. A linear gradient of 20 to 80% % solvent B was applied for 70 minutes 
followed by a column wash for 20 minutes using 10% solvent B. The HPLC retention time, cone voltage 
and collision energy were optimised using synthetic proteotypic peptides for cofilin-1 (LGGSAVISLEGKPL, 
EILVGDVGQTVDDPYATFVK and YALYDATYETK), p23 (DVNVNFEK) and AOC3 (YQLAVTQR, EALAIVFFGR and 
SPVPPGPAPPLQFYPQGPR) (Supplementary Table 1).  Calibration curves were prepared with the 
synthetic peptides (Supplementary Figure 2) before quantitative analysis of trypsin digests of fresh 
protein extracts from cell lines (amol/cell) and patient biopsies (amol/mg tissue).  
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Tissue microarray (TMA) analysis. Sections were prepared from 361 cases of breast cancer 
represented on TMAs as described previously10. In parallel TMA sections, antibodies to cofilin-1 (anti-
cofilin-1 rabbit polyclonal antibody, 1/5000 dilution, Abcam, Cambridge, UK,) or p23 (anti-p23 rabbit 
polyclonal antibody, 1/24000 dilution, Sigma, Dorset, UK) were applied for 1 hour at room temperature. 
Slides were washed with PBS before incubation with horse radish peroxidise (HRP)-conjugated 
secondary antibody (Santa Cruz Biotechnologies, Heidelberg, Germany) at room temperature for 40 
minutes. Visualisation of bound antibodies was performed using diaminobenzidine (En-vision, Dako, Ely, 
UK), followed by haematoxylin counterstaining, dehydration and mounting with cover slips. 
Immunohistochemistry for cofilin-1 was evaluated by SuS, supervised by AMH, using an adapted Allred 
scoring scheme previously described for estrogen receptor11, i.e. the proportion of cell stained (0 = no 
cells stained, 1= 1%, 2 = 1-10%, 3 = 10-33%, 4 = 34-66% and 5 = 67-100%) and the intensity of staining (0 
= negative, 1 = weak, 2 = moderate and 3 = strong). The intensity staining score of 0-1 was interpreted as 
the absence and score of 2-3 as the presence of cofilin-1 in the tissue. p23 IHC was assessed according 
to the system described previously12, which scored cytoplasmic (0 = no cytoplasmic staining, 1+= weak 
staining, 2+ =intermediate staining 3+ = strong staining) and nuclear (0 = no positive nuclei, 1+= weak 
staining, 2+ =intermediate staining 3+ = strong staining) staining independently. Statistical analysis was 
performed using PRISM 5.0 software (GraphPad Software Inc., San Diego, California, USA). 
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Results and Discussion  
Proteomics analysis. Three iTRAQ experiments were performed for the proteomic analysis of 
matched normal and diseased tissues from 10 patients with benign pathologies or breast cancer. 
Histopathology results categorised the tumors into fibroadenoma, DCIS and invasive ductal carcinoma. 
With the exception of one fibroadenoma biopsy (patient 1), which was prepared in triplicate and used in 
each of the three experiments for inter-experiment variation, sets of patients samples were selected 
randomly (Table 1). Following filtering to remove proteins detected only by single peptides or no iTRAQ 
data, 874 proteins (4,812 total peptides) were identified in experiment A, 790 proteins (4,361 peptides) 
in experiment B and 814 proteins (4,768 peptides) in experiment C. A non-redundant list of 1406 
proteins was prepared, of which 402 proteins were detected in all three experiments (Figure 1A), each 
constituent therefore imparting quantitative data in the form of iTRAQ ratios for each patient 
(Supplementary Table 2).   
Each protein iTRAQ ratio for each patient was normalised, using the average peptide iTRAQ 
ratio, so that a heat map was created that enabled comparison of specific protein changes between 
each patient and across disease states (Figure 1B). PCA analysis of the tumor:normal ratio values for 
each patient clustered datasets broadly by disease state (Supplementary Figure 3). The separation 
between patients with invasive carcinoma and other stages can be seen along the first principal 
component (pc1), which accounts for 31% of the variance in the data. In two dimensions, there is no 
distinction between patients with fibroadenoma and those with DCIS, though samples from patient 1 
appear to cluster separately, but consistently, across the three experiments. The dispersion of invasive 
carcinoma patients reflected variations in individual protein ratios, but showed clear differences from 
the fibroadenoma and DCIS groups. Examination of the loadings indicated that proteins cofilin-1, p23, 
60S ribosomal protein L24, cysteine-rich protein 1 and cysteine and glycine-rich protein 1 were most 
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responsible for the variance along pc1. All have high values for the ratios, indicating increased 
expression levels in tumor tissue. 
The proteins common to all three experiments were subject to statistical analysis to identify 
those that were significantly increased or decreased in tumor compared to normal for each patient.  The 
upper and lower 5%, 10% and 25%-ile groups of proteins were determined for each patient. The 
frequency with which each protein appeared in a percentile cluster was recorded to identify those that 
were associated with each disease state. Greater significance was given to those proteins that occurred 
with the same frequency but in a lower percentile group (5%>10%>25%). Hence, significant proteins 
were defined as those with tumor-to-normal ratios in the upper or lower 5% or 10% of the total (402 
common proteins), for ≥3 of 5 fibroadenoma, ≥2 of 3 DCIS or ≥3 of 4 invasive carcinoma patients and in 
the upper or lower 25% for ≥4 of 5 fibroadenoma, 3 of 3 DCIS or 4 of 4 invasive carcinoma patients. 
Previously, we had segregated proteins based on their predominant localisation – intracellular, 
extracellular or blood-based7. However, in the present study all 402 proteins were analysed together. 
Gene Ontology based localisation was applied, identifying proteins as intracellular (64%), membrane-
bound (5%), extracellular (stromal) (13%) or serum/blood-based (18%). Of 69 proteins that were 
decreased in at least three of four invasive carcinomas compared to the equivalent normal tissue, 39 
originated from serum (for example, immunoglobulins, globins, lipoproteins, transport proteins and 
complement factors). These proteins were most likely lower due to the gross decrease in vasculature, 
and consequently lower blood content, in tumors compared to normal breast tissue, and therefore 
excluded from further consideration. This left 59 proteins that were significantly increased or decreased 
(Table 2).  
In a previous study of matched normal and tumor tissues from six patients, by 2D gel 
electrophoresis and MS analysis, 315 proteins were identified of which 57 were differentially expressed 
in individual cases including cofilin-1, profilin, peroxiredoxin 1, heterogeneous nuclear ribonucleoprotein  
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A2/B1 which were also increased in our study13. Proteomic profiling of normal and infiltrating ductal 
carcinomas from 10 Tunisian patients, using non-equilibrium pH gradient electrophoresis and MALDI MS 
peptide fingerprinting identified 20 proteins that were significantly changed14. As with our results, 
immunoglobulin G was observed to be decreased and peptidyl prolyl isomerase A, cofilin-1, 
heterogeneous nuclear ribonucleoprotein A2/B1, and phosphoglycerate kinase 1 were increased. Other 
proteins that we identified with significantly altered levels have also been shown by others to be 
differentially expressed in breast cancer models. These include cytokeratin-1515, cytokeratin-1916, 
cytokeratin-1817, cytokeratin-817-18, prolactin-inducible protein19, 20, calreticulin21, 22, small breast 
epithelial mucin23, 24, peptidyl-prolyl cis-trans isomerase A25, p2312, 26, 27, transcription intermediary 
factor 1-beta28, glyceraldehyde-3-phosphate dehydrogenase29, triosephosphate isomerase25, protein 
disulfide-isomerase A322, protein disulfide-isomerase30 and tropomyosin alpha-3 chain22, which were all 
increased, and alpha-1-acid glycoprotein 120, caveolin-110, 31, adipocyte fatty acid-binding protein32, 33,  
perilipin34 and polymerase I and transcript release factor35 were all decreased. 
STRING analysis emphasised that the majority of the differentially expressed subset of 59 
proteins interact within established complexes or functional relationships (Figure 2). IPA Upstream 
regulator analysis provided evidence of 13 genes exhibiting a response associated with Myc oncogene 
activation (up-regulated – TPI1, PPIA, HSPE1, HNRPD, HMGN2, EEF2, DBI, CRIP1, COX6B1 and down-
regulated – SUCLA2, CRYAB, COL4A1, CAV1) (p<5.05E-09), four genes with Ca+binding protein S100P 
activation (up-regulated – CFL1, KRT19, KRT8 and KRT18) (p<7.19E-09) and seven with folate receptor 1 
activation (regulation of GLRX, TPI1, PFN1, CAV1, LAMB2, CAT, and AOC3)(p<8.39E-09)(Supplementary 
Figure 4). Myc, S100P and folate receptor 1 over expression or malfunction have been associated with 
breast cancer progression36,37,38. Key networks correlating with the identified proteins were associated 
with cell morphology, cellular assembly and organisation, free radical scavenging and cell-to-cell 
signalling (Supplementary Figures 5a-c). Reduced levels of extracellular superoxide dismutase and 
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membrane-bound copper amine oxidase, both of which produce hydrogen peroxide would results in 
lower levels of toxic reactive oxygen species (ROS) in the interstitial fluid surrounding the cancer cells, 
thereby improving the proliferative milieu. Increased expression of peroxiredoxin-1 and -5, along with 
redox regulating proteins, glutaredoxin-1 and thioredoxin, would succeed in reducing intracellular ROS 
levels and further enhance the environment for growth. Catalase, which would also neutralise hydrogen 
peroxide and exhibited reduced levels, may reflect a more complex expression profile as it is expressed 
in erythrocytes, which like other blood proteins observed in our results, is extensively decreased in 
tumor compared to normal tissues. 
A group of lipid transport and metabolism proteins (fatty acid binding protein 4, hormone 
sensitive lipase, perilipin, carboxylesterase 1, EH domain-containing protein 2, caveolin-1, polymerase I 
and transcript release factor) were decreased in tumor compared to normal tissues. This may simply 
reflect their predominant expression in adipocytes which were substantially reduced in tumor. However, 
the diminished levels of caveolin-1 may also relate to its role in tumor suppression, which as a 
consequence would result in cancer progression. Loss of caveolin-1 in cancer-associated fibroblasts has 
previously been shown to correlate with poor prognosis in breast cancer10, but increased expression has 
also been linked with metastasis and anti-cancer drug resistance39.  
TRIM28, is a multi-functional E3 SUMO-protein ligase, increased in tumor compared to normal, 
which ubiquitinates p53, leading to its proteasomal degradation, thereby removing a tumor suppressor 
and preventing apoptosis. Network analysis suggested that, through ubiquitination, TRIM28 may control 
the activity of other identified up-regulated proteins, including small acidic protein, cysteine-rich protein 
1, SH3 domain-binding glutamic acid-rich-like protein, cytochrome c oxidase subunit VIb isoform 1, 60S 
ribosomal protein L24, elongation factor 1-delta, histone H2A type 1-H and glucosidase 2 subunit beta. 
Three proteins, cofilin-1, p23 and AOC3, were selected to validate the proteomics approach 
undertaken. Cofilin-1 was an example of a protein identified with high confidence (20 peptides, 105 
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spectra, average Mascot score of 462 and 84.3% sequence coverage across the three experiments) as 
increased in tumor compared to normal tissue (average iTRAQ ratio of 1.836 for four invasive carcinoma 
measurements) and highlighted by PCA as significantly contributing to the invasive carcinoma signature. 
p23, also increased in tumor compared to normal tissue, is a protein detected with low confidence (3 
peptides, 6 spectra, average score = 31, 18.8% sequence coverage and average iTRAQ ratio of 2.161, but 
also strongly associated by PCA with the invasive carcinoma signature), therefore requiring verification 
by alternative methods. AOC3 was an example of a protein identified with confidence and decreased in 
tumor compared to normal tissues (11 peptides, 56 spectra, average score = 272, 16.4% sequence 
coverage and average iTRAQ ratio of 0.308).   
Cofilin-1 plays a pivotal role in directing actin polymerisation into filaments that form 
lamellipodia, then invadopodia, to push the membrane envelope of metastatic cells on the first steps 
towards cell motility and invasion40. It has been shown to be over-expressed in other cancer tissues, in 
addition to breast tumors13-14, using immunohistochemistry (esophageal squamous cell carcinoma41, gall 
bladder squamous cell and adenosquamous carcinomas42, ovarian43, 44, non-small cell lung cancer45 46) 
and 2D gel electrophoresis with MS identification (oral squamous47, prostate48, renal49). p23 is a 
multifunctional protein that modulates the activity of aryl hydrocarbon receptor and, in conjunction 
with HSP90, increases the affinity of steroid hormone receptors for their respective ligands12, 50, 51. It is 
also involved in the recruitment of steroid receptors and telomerase to the nucleus where they regulate 
transcriptional expression of target genes52, it stabilises specific kinases and has glutathione-dependent 
cytoplasmic prostaglandin E synthase 3 enzyme activity53. The role of p23 in breast cancer has also been 
described, with over-expression enhancing ER-dependent transcriptional events including promoting 
transition from non-invasive to invasive cells through activation of metastasis-related genes and has 
been established as a potential target to prevent development of secondary tumors. AOC3 is a 
membrane protein up-regulated in adipocyte differentiation and therefore expected to be reduced in 
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tumor tissue where adipocyte composition is lower than normal tissues. Amino oxidases have been 
shown to inhibit tumor growth. The decreased levels of AOC3 observed in our proteomics analysis may 
be associated with removal of a repressive factor which consequentially enables tumor growth54 and 
therefore warrants further investigation. 
Western blot analysis of cofilin-1, p23 and AOC3 was performed on protein extracts from breast 
cancer cell lines and tissues. Cell lines representative of five breast cancer phenotypes (Luminal A, 
Luminal B, basal-like, Claudin-low and HER2), normal breast cell lines and normal primary breast 
epithelial cells were analysed for expression profile screening (Supplementary Figure 6A and B). Cofilin-1 
was ubiquitously expressed in all cell lines tested with a single band at molecular weight of 21.0 kDa 
(theoretical molecular weight = 18.5 kDa), p23 was observed as a double band with the weaker, sporadic 
band A at 22.6 kDa and stronger band B at 20.5 kDa (expected molecular weight from sequence = 18.7 
kDa) in breast cancer cell lines, normal breast cell lines and primary epithelial cells. AOC3 was also 
generally well expressed across all the cell lines despite normally being associated with adipocytes, but 
was much weaker in normal cell lines compared to cancer cell lines. A main band of 132.0 kDa and 
weaker band of 87.9 kDa (expected molecular weight = 84.6 kDa) were detected. As AOC3 has 6 N-
linked and 1 O-linked glycosylation sites, a higher molecular weight than that calculated from the amino 
acid sequence was expected on SDS PAGE.  
Matched tissues from patients with invasive carcinoma indicated the presence of cofilin-1 in the 
tumor samples and either lower or complete absence of the protein in the equivalent normal tissues by 
Western blot analysis (Figure 3A). As with cell line analysis, p23 was observed as two bands, with band B 
stronger than band A, and the former observed to be differentially expressed between tumor and 
normal tissues. Also, in support of the proteomics results, AOC3 was detected in most normal samples, 
but absent from tumors (Figure 3A). Cofilin-1 was also analysed in matched normal and diseased tissues 
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from fibroadenoma and DCIS patients. In both cases, cofilin-1 levels were either unchanged or 
marginally increased in tumors compared to the equivalent normal sample (Figure 3B). 
MRM MS was performed using proteotypic peptides for cofilin-1 (analysis of three unique 
peptides), p23 (one peptide) and AOC3 (three peptides). Calibration curves were prepared using 
synthetic peptides, each of which exhibited a linear response over 3 orders of magnitude in the range of 
10ng/ml to 10g/ml (Supplementary Figure 2).  Cofilin-1 and p23, but not AOC3, were detected in all cell 
lines. MRM MS analysis confirmed the ubiquitous presence of cofilin-1 in the range of concentrations of 
360 (MCF7, luminal A) to 860 (BT474, luminal B) amol/cell (average of 3 measurements for each peptide 
for each cell line) for cancer cell lines, but lower levels for normal cell lines 67-73 amol/cell 
(Supplementary Figure 7A).  Somewhat surprisingly, cofilin-1 levels were low in MDA-MB-468 cells (383 
amol/cell), which are derived from an aggressively invasive basal-like tumor. This could be due the cells 
down-regulating cofilin-1 expression once they have achieved an invasive status or due to phenotypic 
changes resulting from cell line immortalisation. Similar to cofilin-1, p23 was detected in all, ranging 
from 11 (Hs578-T, Claudin-low) to 60 (MDA-MB-453, HER2+) amol/cell (average of 2 measurements for 
one peptide) for cancer cell lines and lower levels for normal cells – 4 to 7 amol/cell (Supplementary 
Figure 7B).  
MRM MS analysis of cofilin-1, p23 and AOC3 was performed on fresh trypsin digests of protein 
extracts from matched biopsies of 5 invasive carcinoma, 1 DCIS and 1 fibroadenoma patients.  The 
results corroborated previous observations with significantly higher levels of cofilin-1 and p23 in tumor 
than normal for invasive carcinoma patients, and the reverse for AOC3 (Figure 4). Similarly, there was 
little or no change in the levels of the proteins in fibroadenoma or DCIS patients. The 3 peptides selected 
for AOC3 were from different regions of the protein sequence to allow for post-translational truncation. 
The MRM MS results indicated that only one of the peptides (YQLAVTQR) was detected in breast cancer 
tissues and none in the cell lines. Western blot results of AOC3, using an antibody generated to the 
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recombinant protein (Gly27-Asn763) indicated that the protein was essentially intact in cell lines and 
breast tissues. The most likely explanation for the discrepancy is that the levels of AOC3 were much 
lower in epithelial cell lines and consequently not observed above the limit of detection by MRM MS, 
compared to the amounts present in adipocyte-rich normal tissues or detected in Western blots.  
TMAs of 361 breast cancers were prepared for cofilin-1 and p23 (representative images are 
shown in Supplementary Figure 8). Cofilin-1 was scored based on the proportion of cancer cells stained 
and intensity of intracellular cofilin-1 staining as a measure of expression. Of the arrays, 81% stained 
positively for cofilin-1. Intensity of staining correlated with proportion of cells stained and was positively 
associated with tumor grade and tumor type (invasive ductal and invasive lobular) (Table 3A). p23 
staining was differentiated into nuclear and cytoplasmic sub-cellular localisation. In agreement with 
Simpson et al12, strong cytoplasmic staining also correlated with strong nuclear staining (Table 3B). Like 
cofilin-1, p23 correlated positively with invasive ductal and invasive lobular carcinoma, but also with ER 
expression status.  
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Conclusions  
There has been extensive research to discover biomarkers to provide clinicians with accurate 
information that will support the best outcome for the patient, whether this is for early detection, 
selection of therapy, or to predict responsiveness or resistance to treatment. Our objective is to identify 
proteins that correlated with breast tumor progression, starting from benign through to malignant 
states. We elected to use breast tissue biopsies as the most direct source associated with the disease 
and generated samples that comprised proteins from the various constituent epithelial, fibroblast, myo-
epithelial cell types, stroma, lymphatic system and vasculature. Quantitative proteomics revealed a set 
of proteins that were increased or decreased in diseased compared to normal tissues, the majority 
associated with invasive carcinoma. Some of these have already been linked with breast cancer and 
many affect key cellular events connected to tumorigenesis. Analysis of selected target proteins using 
complementary methods confirmed the changes observed with iTRAQ quantitation.  
The cofilin pathway has previously been established as a key step in the invasiveness and 
metastasis of breast cancer40, however our results represent the most comprehensive analysis of cofilin-
1 as a possible biomarker of the disease. Our results indicated that cofilin-1 is ubiquitously expressed in 
breast epithelial cells. The protein was detected in all cancer and normal cell lines as well as primary 
breast epithelial cells. This included highly invasive and metastatic basal-like and Claudin-low 
phenotypes, which are predominantly defined as triple negative. Cofilin-1 activity in cell motility, which 
forms the initial step of invasiveness, is stimulated by EGF receptor55.  In the absence of HER2, triple 
negative breast cancers may activate the cofilin pathway through other members of the EGF receptor 
family or independent mechanisms. The presence of cofilin-1 in some normal tissues from 
fibroadenoma and DCIS patients may reflect the epithelial cell content however there was also evidence 
of an increase in matched tumor samples. The extent to which cofilin-1 was detected in tissues is 
possibly due to epithelial cell content, which is lower in normal compared to tumor specimens, rather 
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than increased expression. Tissue microarray results, however, suggest that cofilin-1 expression 
correlates with tumor grade which relates to clinical outcome, establishing it as a strong candidate for 
further validation as a prognostic biomarker. This warrants further investigation with a larger patient 
cohort to determine if cofilin-1 is a biomarker of early breast cancer or an indicator of aberrant benign 
and malignant growth. 
p23 exhibited many similar properties to cofilin-1 - detected in all cell lines (though with greater 
variability) and increased in invasive carcinomas compared to normal tissue (p23 was below the levels of 
detection in fibroadenoma and DCIS tissues using Western blotting and MRM MS). From TMA analysis, 
p23 was positively associated with ER status, correlating with its role as a modulator of estrogen 
receptor (ER)-dependent transcriptional activity. The activities of p23 affect different targets based on 
sub-cellular localisation. In the cytoplasm it is part of the HSP90 complex that regulates steroid receptor 
ligand binding capacity, whereas in the nucleus it augments transcriptional activation activity of steroid 
receptors56.  Our results indicated a direct correlation between cytoplasmic and nuclear levels as well as 
positive association with invasive ductal and lobular tumors.  Increased expression of p23 in MCF7 cells 
was shown to convert them into an aggressive invasive phenotype51. Like cofilin-1, p23 was expressed in 
triple negative phenotype cell lines and has previously been shown to increase metastatic characteristics 
of this phenotype57. In these sources, p23 may be acting through non-steroid receptor mechanisms, 
hence further clinical validation as a breast cancer biomarker would be invaluable. 
 Overall, the results have indicated that proteomics analysis of matched tissues can generate a 
valuable subset of candidate proteins for further investigation. In addition, proteins identified with low 
confidence but are reproducibly detected, such as p23, accurately reflect the expression levels 
corroborated by complementary methods.  Bioinformatics tools assisted the identification of 
relationships and networks between groups of proteins and identified additional targets for biomarker 
validation.  
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Figure Legends 
Figure 1. (A). Venn diagram showing the association of proteins identified in three iTRAQ experiments A, 
B and C. (B). Cluster analysis for the 402 proteins identified in all three experiments with tumor:normal 
iTRAQ ratios for each protein for each patient represented as upper 25 percentile (green), lower 25 
percentile (red) or unchanged (yellow), and ordered by the average iTRAQ ratio for the invasive 
carcinoma patients. 
Figure 2. Protein-protein interactions determined by STRING analysis for the increased (green border), 
decreased (red border) and associated unaffected proteins (amber border) in tumor compared to 
normal tissues (Table 2). Thicker lines represent stronger confidence of association between proteins. 
Proteins associated with redox equilibrium (A), lipid transport/metabolism (B), protein folding (C), cell 
assembly, morphology and organisation (D) and mitochondrial localisation (E) are clustered together 
(−−−−−−). 
Figure 3. Western blot analysis (A) cofilin-1, p23, AOC3 and -actin expression in matched normal and 
tumor tissues of four invasive carcinoma patients, (B) cofilin-1 expression in matched normal and tumor 
tissues of fibroadenoma and DCIS patients, 
Figure 4. MRM MS – breast cancer patent tissues - concentrations of cofilin-1 (A), p23 (B) and AOC3 (C) 
in amol/mg of tissue  
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Tables  
Table 1. Details of patients 1 to 10 including histopathology grade, age, tumor size, ER, PR and L/N status 
and iTRAQ reagent.  
 
Table 2. Summary of the significant up- and down-regulated proteins. Significant proteins were defined 
at those with tumor-to-normal ratios in the upper or lower 5% or 10% of the total (402 common 
proteins), for at least 3 of 5 fibroadenoma, 2 of 3 DCIS or 3 of 4 invasive carcinoma patients and in the 
upper or lower 25% for at least 4 of 5 fibroadenoma, 3 of 3 DCIS or 4 of 4 invasive carcinoma patients. u 
= up-regulated and d = down-regulated proteins in tumor compared to normal breast tissue. 
 
Table 3. Immunohistochemical detection correlated to the clinicopathological features of the TMA 
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Table 1. Details of Cyprus patients 1 to 10 including histopathology grade, age, tumor size, ER, PR and L/N status and iTRAQ reagent. 
 
Patient Histopathology Grade Age Lesion Menopause ER PgR L/N iTRAQ label
cm status T/N
patient 3 DCIS high 46 1.5 pre - - 0/2 +ve 114/113
patient 5 invasive ductal carcinoma ND 50 3.0 pre + + 9/22 +ve 116/115
patient 4 invasive ductal carcinoma II 80 4.0 post + - 17/23 +ve 118/117
patient 1 fibroadenoma N/A 24 4.0 pre + + N/A 121/119
patient 1 fibroadenoma N/A 24 4.0 pre + + N/A 114/113
patient 6 invasive ductal carcinoma I 53 2.0 post + + 0/4 +ve 116/115
patient 2 invasive ductal carcinoma III 76 3.5 post - - 6/9 +ve 118/117
patient 7 DCIS high 64 1.8 post - - 1 +ve 121/119
patient 9 DCIS low 76 3.0 post - - 0/10 114/113
patient 8 fibroadenoma N/A 45 2.5 pre + + N/A 116/115
patient 1 fibroadenoma N/A 24 4.0 pre + + N/A 118/117
patient 10 fibroadenoma N/A 27 2.0 pre + + N/A 121/119
ND = not determined
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Table 2. Summary of the significant up- and down-regulated proteins in IC and DCIS 
 
  
Accession Gene Protein MW [kDa] pI ave score ave # ave SC ave IC ratio ad. ad. ad. DCIS DCIS DCIS IC IC IC
5% 10% 25% 5% 10% 25% 5% 10% 25%
TEBP_HUMAN PGTES3 Prostaglandin E synthase 3, p23 18.7 4.2 31 1 9 2.161 3/4 u 3/4 u 3/4 u
TIF1B_HUMAN TRIM28 Transcription intermediary factor 1-beta 88.5 5.4 71 2 4 1.841 2/3 u 2/3 u 2/3 u 2/4 u 2/4 u 3/4 u
SMAP_HUMAN C11orf58 Small acidic protein 20.3 4.4 51 1 5 1.840 2/3 u 3/4 u 3/4 u 4/4 u
RL24_HUMAN RPL24 60S ribosomal protein L24 17.8 12.0 91 3 16 1.840 2/4 u 3/4 u 3/4 u
COF1_HUMAN CFL1 Cofilin-1 18.5 9.1 462 10 42 1.836 2/4 u 3/4 u 4/4 u
SFRS3_HUMAN SRSF3 Splicing factor, arginine/serine-rich 3 19.3 12.3 88 3 17 1.835 3/5 u 4/4 u
CRIP1_HUMAN CRIP1 Cysteine-rich protein 1 8.5 10.2 82 3 31 1.786 2/3 d 2/4 u 3/4 u 3/4 u
SH3L1_HUMAN SH3BGRL SH3 domain-binding glutamic acid-rich-like protein 12.8 5.1 157 3 31 1.772 2/4 u 3/4 u 4/4 u
CX6B1_HUMAN COX6B1 Cytochrome c oxidase subunit VIb isoform 1 10.2 7.5 80 2 22 1.732 3/5 u 4/5 u
PPIA_HUMAN PPIA Peptidyl-prolyl cis-trans isomerase A 18.0 9.0 835 16 69 1.703 2/4 u 4/4 u 4/4 u
K1C19_HUMAN KRT19 Keratin, type I cytoskeletal 19 44.1 4.9 1352 29 57 1.665 2/3 u 2/4 u 3/4 u 4/4 u
CH10_HUMAN HSPE1 10 kDa heat shock protein, mito. 10.9 9.4 232 5 45 1.657 3/4 u 3/4 u 3/4 u
K2C8_HUMAN KRT8 Keratin, type II cytoskeletal 8 53.7 5.4 1117 24 43 1.639 2/3 u 3/3 u 3/4 u 3/4 u
MUCL_HUMAN MUCL1 Small breast epithelial mucin 9.0 4.2 47 2 9 1.630 2/3 u 3/4 u 3/4 u 3/4 u
CALR_HUMAN CALR Calreticulin 48.1 4.1 353 10 24 1.614 4/4 u
SFRS2_HUMAN SRFS2 Splicing factor, arginine/serine-rich 2 25.5 12.4 65 2 6 1.591 2/3 u 2/4 u 2/4 u 3/4 u
GLRX1_HUMAN GLRX Glutaredoxin-1 11.8 9.7 64 2 23 1.584 2/3 d 2/3 d 2/4 u 3/4 u 3/4 u
HMGN2_HUMAN HMGN2 Nonhistone chromosomal protein HMG-17 9.4 10.5 103 3 30 1.557 2/4 u 2/4 u 3/4 u
EF1D_HUMAN EEF1D Elongation factor 1-delta 31.1 4.8 223 6 18 1.554 4/4 u
GLU2B_HUMAN PRKCSH Glucosidase 2 subunit beta 59.4 4.2 186 7 10 1.549 3/4 u 4/4 u
PRDX1_HUMAN PRDX1 Peroxiredoxin-1 22.1 9.2 657 13 52 1.532 2/4 u 2/4 u 3/4 u
H2A1H_HUMAN HIST1H2AH Histone H2A type 1-H 13.9 11.3 459 9 47 1.513 2/3 u 4/4 u
TPIS_HUMAN TPI1 Triosephosphate isomerase 26.7 6.5 858 15 63 1.452 4/4 u
HNRPD_HUMAN HNRNPD Heterogeneous nuclear ribonucleoprotein D0 38.4 8.5 235 6 15 1.443 4/4 u
PROF1_HUMAN PFN1 Profilin-1 15.0 9.4 691 11 57 1.402 4/4 u
K2C7_HUMAN KRT7 Keratin, type II cytoskeletal 7 51.4 5.4 1158 23 44 1.398 2/3 u 3/3 u 4/4 u
TPM3_HUMAN TPM3 Tropomyosin alpha-3 chain 32.8 4.5 557 16 36 1.387 4/4 u
PDIA3_HUMAN PDIA3 Protein disulfide-isomerase A3 56.7 5.9 817 21 37 1.383 4/4 u
ACBP_HUMAN DBI Acyl-CoA-binding protein 10.0 6.2 267 6 66 1.367 3/3 u 3/4 u
RS25_HUMAN RPS25 40S ribosomal protein S25 13.7 10.6 28 1 6 1.341 2/3 u 2/3 u 3/3 u
DSCAM_HUMAN DSCAM Down syndrome cell adhesion molecule 222.1 8.5 62 3 2 1.259 2/3 u 2/3 u 2/3 u
K1C18_HUMAN KRT18 Keratin, type I cytoskeletal 18 48.0 5.2 581 17 29 1.197 2/3 u 3/3 u 3/4 u
EF2_HUMAN EEF2 Elongation factor 2 95.3 6.4 264 7 11 1.035 4/5 d
TKT_HUMAN TKT Transketolase 67.8 8.5 182 6 9 0.826 3/3 u
NQO1_HUMAN NQ01 NAD(P)H dehydrogenase 30.8 9.4 47 1 6 0.809 2/3 u 2/3 u 2/3 u
ATPB_HUMAN ATP5B ATP synthase subunit beta, mito. 56.5 5.1 411 11 26 0.805 2/3 u 3/3 u
COR1C_HUMAN CORO1C Coronin-1C 53.2 6.7 39 1 3 0.772 4/5 d
CMA1_HUMAN CMA1 Chymase 27.3 10.4 435 8 32 0.711 3/3 d
K1C9_HUMAN KRT9 Keratin, type I cytoskeletal 9 62.1 5.1 253 8 13 0.679 2/3 d 2/3 d 3/3 d
CLM1_HUMAN CD300LF CMRF35-like-molecule 1 32.3 5.5 27 1 4 0.647 3/3 d 3/3 d
PIP_HUMAN PIP Prolactin-inducible protein 16.6 9.3 285 6 45 0.590 2/3 u 2/3 u 3/3 u 3/4 d
EHD2_HUMAN EHD2 EH domain-containing protein 2 61.1 6.0 261 8 16 0.546 4/4 d
DPYL2_HUMAN DPYSL2 Dihydropyrimidinase-related protein 62.3 5.9 124 3 5 0.544 2/3 u 4/4 d
CAV1_HUMAN CAV1 Caveolin-1 20.5 5.6 128 3 18 0.489 4/5 d 2/3 d 4/4 d
LAMB2_HUMAN LAMB2 Laminin subunit beta-2 196.0 6.1 170 6 5 0.474 4/4 d
CO4A1_HUMAN COL4A1 Collagen alpha-1(IV) chain 160.5 9.4 196 5 5 0.464 4/4 d
EST1_HUMAN CES1 Liver carboxylesterase 1 62.5 6.2 79 3 5 0.426 3/4 d 4/4 d
SODE_HUMAN SOD3 Extracellular superoxide dismutase [Cu-Zn] 25.8 6.2 231 5 23 0.420 4/4 d
PLIN_HUMAN PLIN1 Perilipin 55.9 6.0 529 11 29 0.416 3/3 u 3/3 u 2/4 d 2/4 d 4/4 d
FHL1_HUMAN FHL1 Four and a half LIM domains protein 1 36.2 10.5 194 6 16 0.405 3/4 d 4/4 d
SUCB1_HUMAN SUCLA2 Succinyl-CoA ligase [ADP-forming] beta-chain, mito. 50.3 7.7 81 1 2 0.403 3/4 d 4/4 d
PTRF_HUMAN PTRF Polymerase I and transcript release factor 43.4 5.4 389 11 22 0.402 2/3 d 2/4 d 3/4 d 4/4 d
ALDH2_HUMAN ALDH2 Aldehyde dehydrogenase, mitochondrial 56.3 6.8 117 4 7 0.401 2/4 d 3/4 d 4/4 d
GPDA_HUMAN GPD1 Glycerol-3-phosphate dehydrogenase [NAD+], cyto. 37.5 5.8 200 5 19 0.399 2/4 d 3/4 d 4/4 d
CATA_HUMAN CAT Catalase 59.7 7.0 297 7 17 0.399 2/4 d 3/4 d 4/4 d
CRYAB_HUMAN CRYAB Alpha crystallin B chain 20.1 6.9 89 3 16 0.327 3/4 d 4/4 d 4/4 d
AOC3_HUMAN AOC3 Membrane copper amine oxidase 84.6 6.1 272 9 10 0.308 3/4 d 4/4 d 4/4 d
LIPS_HUMAN LIPE Hormone-sensitive lipase 116.5 6.2 49 1 2 0.287 3/4 d 4/4 d 4/4 d
FABPA_HUMAN FABP4 Fatty acid-binding protein, adipocyte 14.7 7.5 349 6 41 0.256 2/3 d 4/4 d 4/4 d 4/4 d
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Table 3. Immunohistochemical detection correlated to the clinicopathological features of the TMA 
cohort. A. cofilin-1 and B. p23 
 
a - p was determined by Fisher test for cofilin-1 characteristics except age for which t test was used 
b - p was determined by One way ANOVA for p23 characteristics except age for which t test was used 
  
A BCharacteristic 0&1 (60) 2&3(263) p valuea
Age Years













Invasive Ductal 41 217
Invasive Lobular 8 22
Other 11 24
Lymph Node Status 0.9b
No 26 112
N1-3 31 137










Characteristic 1+(24) 2+(150) 3+(131) 1+vs2+vs3+
b
Age Years
Mean ±SD 62±12.12 60±14.6 57±14.13 0.5
Nuclear p23 <0.0001
0 1 0 0
1+ 12 1 0
2+ 8 20 0
3+ 3 129 131
Grade 0.3
I 8 29 33
II 7 72 50
III 9 49 48
Type <0.0001
Invasive Ductal 14 122 106
Invasive Lobular 2 17 11
Other 8 11 14
Lymph Node Status 0.6
No 9 70 56
N1-3 12 71 71
No Node taken 3 9 4
ER Status 0.01
Positive 14 113 112
Negative 7 28 17
Tumour size (mm) 0.4
≤10 1 17 17
>10 23 127 112
Metastasis 0.07
0 10 85 72
1 7 18 25
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Synopsis 
As part of an initiative to identify early indicators of breast cancer, quantitative proteomics was 
performed on matched normal and tumor tissues from stage-specific breast cancer patients identifying 
59 proteins that were significantly changed. The proteins were associated with cell morphology, cellular 
assembly and organisation, free radical scavenging and cell-to-cell signalling. The results were 
corroborated by Western blotting and MRM MS of cofilin-1 and p23, both increased, and AOC3, 
decreased in tumor compared to normal tissue.  Widespread expression of cofilin-1 and p23 in an 
invasive carcinoma-centric tissue microarray analysis further validated these candidates as potential 
biomarkers of breast cancer. 
 
Significance 
Despite strong progress in the treatment of breast cancer, the incidence of disease continues to 
increase. There still remains no molecular diagnostic for the early detection of breast cancer. By 
studying proteomics changes in matched normal and benign or malignant tumor tissues from patients 
with different stages of the disease, our objective was to identify candidate biomarkers for clinical 
validation.  
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Supporting Information.  
Supplementary Tables  
Supplementary Table 1, MRM MS - proteotypic peptide properties  
Supplementary Table 2, summary of the quantitative proteomic analysis of 402 proteins identified in all 
three experiments. For each protein, the SwissProt accession number, name, theoretical molecular 
weight and pI and for each protein in each experiment (A, B and C), Mascot scores, number of peptides, 
sequence coverage (SC) are provided. In addition, for each protein in each experiment, for each patient, 
normalised median ratio, the number of iTRAQ measurements (#), and CV(%) are included.   
Supplementary Figures  
1. Proteomics workflow 
2. MRM MS - calibration curves for proteotypic peptide standards 
3. Principle component analysis of 12 iTRAQ proteomics datasets for 10 patients 
4. Upstream regulator analysis for significantly increased and decreased proteins associated 
5. Network analysis for significantly increased and decreased proteins associated with cell 
morphology, cellular assembly and organisation (a), free radical scavenging (b) and cell-to-cell 
signalling (c) 
6. Western blot analysis of cofilin-1, p23, AOC3 and b-actin expression in (A) breast cancer cell 
lines of defined phenotype, (B) MCF-7 breast cancer cell line (included as a reference) normal 
breast cell lines and (1o ) primary cells. Bands marked A and B identify the 22.6kDa and 20.5kDa 
p23 proteins respectively.  
7. MRM MS – breast cancer cell lines with concentrations of cofilin-1 (A) and p23 (B) in amol/cell 
8. Representative IHC images for cofilin-1 staining, (i) strong expression (proportion score = 5, 
intensity score = 3) and (ii) no expression (proportion score = 0, intensity score = 0), and p23 
staining, (iii) strong nuclear score of 3 and strong cytoplasmic expression score of 3, and (iv) 
negative nuclear score of 0 and weak cytoplasmic expression score of 1.  
